The Role of DHEA and Androgens in Diabetes: Beyond Glucose Control

Diabetes mellitus now affects more than 500 million individuals worldwide, a number projected to climb past 700 million by 2045. While clinical attention rightly centers on glycemic targets, the disease creates a much wider endocrine disturbance. Insulin resistance and hyperglycemia disrupt multiple hormonal feedback loops, particularly affecting the adrenal and gonadal axes. Among the most overlooked yet significant players are dehydroepiandrosterone (DHEA) and the androgens—testosterone, dihydrotestosterone (DHT), and their precursors. These steroid hormones are increasingly recognized as key modulators of insulin sensitivity, body composition, and systemic inflammation. This article provides a comprehensive examination of how DHEA and androgens interact with diabetes pathophysiology, reviews the clinical evidence for their therapeutic use, and offers actionable guidance for clinicians and patients seeking to integrate hormonal balance into diabetes care.

Understanding DHEA: The Master Precursor

DHEA is a steroid hormone synthesized primarily in the zona reticularis of the adrenal cortex, with minor contributions from the gonads and brain. It circulates in two forms: free DHEA and its sulfated conjugate, DHEAS. DHEAS acts as a stable, long-lived reservoir that can be converted back into DHEA in peripheral tissues. DHEA itself has weak androgenic activity; its primary physiological significance is as a precursor to testosterone and estradiol via the action of enzymes such as 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase, and aromatase. Production peaks in the mid-20s and then declines by roughly 2% per year, dropping to 10–20% of peak levels by age 80. This age-related decline is accelerated in chronic diseases, including type 2 diabetes, where adrenal function is further suppressed by hyperglycemia, insulin resistance, and elevated inflammatory cytokines.

Multiple lines of evidence support a direct role for DHEA in glucose homeostasis. At the cellular level, DHEA modulates the activity of peroxisome proliferator-activated receptors (PPARs), particularly PPARα and PPARγ. PPARα induces fatty acid oxidation in the liver and skeletal muscle, reducing intramyocellular lipid accumulation that impairs insulin signaling. PPARγ activation promotes adipocyte differentiation and increases the storage capacity of subcutaneous fat, which is associated with better insulin sensitivity than visceral fat accumulation. In skeletal muscle, DHEA enhances glucose uptake by increasing the translocation of GLUT4 transporters to the cell membrane, an effect mediated partly through AMP-activated protein kinase (AMPK). Animal studies consistently show that DHEA administration improves insulin sensitivity, reduces hepatic gluconeogenesis, and lowers fasting glucose levels.

Human data are more nuanced but point to clinically meaningful effects in specific populations. A 2022 meta-analysis of 18 randomized controlled trials found that DHEA supplementation significantly reduced fasting glucose (mean difference −5.2 mg/dL) and HbA1c (−0.3%) in individuals with metabolic syndrome or type 2 diabetes. The effects were larger in those with low baseline DHEAS levels, suggesting that baseline hormonal status is a critical predictor of response. Studies in healthy older adults without metabolic impairment often fail to show benefit, likely because their insulin sensitivity is already well-maintained. In type 1 diabetes, DHEA supplementation has shown less consistent results, though small trials have noted improvements in hypoglycemia awareness and quality of life.

Inflammation, Oxidative Stress, and DHEA

Chronic low-grade inflammation is a hallmark of type 2 diabetes. Adipose tissue dysfunction, particularly in visceral fat, leads to the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These cytokines activate nuclear factor-kappa B (NF-κB) signaling, which perpetuates insulin resistance and beta-cell damage. DHEA exerts anti-inflammatory effects through multiple mechanisms: it suppresses NF-κB activation by inhibiting IκB kinase (IKK) activity, reduces TNF-α and IL-6 production in macrophages and adipocytes, and enhances the activity of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase. Higher circulating DHEA levels are consistently associated with lower C-reactive protein (CRP) and improved endothelial function—factors that may reduce cardiovascular risk in diabetic patients.

Beyond inflammation, DHEA supports mitochondrial function. It promotes mitochondrial biogenesis through activation of sirtuin 1 (SIRT1) and PGC-1α, and reduces reactive oxygen species (ROS) production by enhancing electron transport chain efficiency. This action is particularly relevant for diabetes-related fatigue, a debilitating symptom that often eludes conventional glucose management. Pilot studies have reported improvements in energy and quality of life with DHEA replacement, though larger trials are needed to confirm these benefits and to clarify whether effects are mediated through improved insulin sensitivity or direct central nervous system actions.

Androgens in Diabetes: A Two-Way Street

Testosterone, the primary androgen, shares a bidirectional relationship with diabetes. Low testosterone is both a consequence of and a contributor to insulin resistance. In men, the prevalence of hypogonadism is roughly 30–40% in those with type 2 diabetes, compared to 10–15% in the general age-matched population. The mechanisms driving this relationship are multifaceted. Chronic hyperglycemia and advanced glycation end-products impair Leydig cell steroidogenic enzyme activity, reducing testosterone synthesis. Hyperinsulinemia and leptin resistance disrupt the hypothalamic-pituitary-gonadal (HPG) axis by suppressing gonadotropin-releasing hormone (GnRH) pulsatility. Additionally, insulin suppresses hepatic production of sex hormone-binding globulin (SHBG), leading to lower total testosterone levels. However, free testosterone may also be low if bioavailability is reduced by competitive binding to albumin.

In women, the relationship is more complex and follows a U-shaped curve. Polycystic ovary syndrome (PCOS), characterized by hyperandrogenism, is a major risk factor for insulin resistance and type 2 diabetes. Elevated androgen levels in PCOS promote visceral adiposity and impair glucose uptake in skeletal muscle. Conversely, after menopause, declining ovarian and adrenal androgen production may contribute to metabolic deterioration, including worsening insulin sensitivity and increased cardiovascular risk. Thus, both extremely high and extremely low androgen levels can be detrimental, making the assessment of free versus total testosterone and consideration of SHBG levels essential.

Testosterone and Body Composition: Muscle, Fat, and Metabolism

Testosterone is a potent anabolic hormone that directly stimulates muscle protein synthesis and inhibits lipoprotein lipase activity in adipose tissue, reducing fat storage. In hypogonadal men, testosterone replacement therapy (TRT) has been shown to reduce visceral adiposity by 10–20%, increase lean body mass by 2–4 kg, and improve insulin sensitivity. Meta-analyses report HbA1c reductions averaging 0.5–1.0% in those with baseline HbA1c above 7%, an effect comparable to some oral hypoglycemic agents. The mechanism is partly mediated through changes in body composition: every kilogram of lean mass gained is associated with improved glucose disposal and lower insulin resistance. Testosterone also directly enhances insulin signaling in adipose tissue and skeletal muscle by upregulating insulin receptor substrate-1 (IRS-1) and GLUT4 expression.

However, TRT is not without risks. The Endocrine Society recommends reserving it for men with confirmed clinical hypogonadism (symptoms plus low morning total testosterone below 300 ng/dL). Potential adverse effects include polycythemia (increased hematocrit), exacerbation of obstructive sleep apnea, and concerns about long-term cardiovascular safety. Recent large-scale trials, such as the TRAVERSE study, have not shown increased major adverse cardiac events when treatment is appropriately monitored, but patients with pre-existing cardiovascular disease require close observation. In women, testosterone therapy is rarely indicated for diabetes management; it is reserved for hypoactive sexual desire disorder under specialist guidance, and even then, with caution due to potential metabolic effects.

DHEA, Cortisol, and the HPA Axis in Diabetes

Chronic hyperglycemia and psychological stress activate the hypothalamic-pituitary-adrenal (HPA) axis, leading to elevated cortisol levels. Cortisol antagonizes insulin action, promotes gluconeogenesis in the liver, and stimulates visceral fat accumulation. It also accelerates muscle protein catabolism and impairs glucose disposal. At the same time, DHEA production is suppressed, creating a high cortisol-to-DHEA ratio—a marker of physiological stress that correlates with worse glycemic control, increased cardiovascular risk, and greater insulin resistance.

DHEA supplementation may help correct this imbalance. By providing substrate for androgen synthesis and directly modulating glucocorticoid receptor activity, DHEA can reduce cortisol’s negative effects. Studies in type 2 diabetes have shown that DHEA administration lowers the cortisol/DHEA ratio and improves markers of insulin sensitivity independent of weight loss. This interplay highlights why clinicians should consider both adrenal and gonadal steroids when evaluating hormonal health in diabetes. A simple morning blood draw for cortisol, DHEAS, and testosterone can provide valuable insight into the patient’s endocrine milieu and guide personalized interventions.

Clinical Considerations for Supplementation

DHEA Dosing, Safety, and Monitoring

DHEA is available over the counter as a dietary supplement, but its regulation is inconsistent. Product quality varies widely; independent testing has found that actual DHEA content can range from 0% to 150% of labeled amounts. Typical doses range from 25 to 100 mg per day, with lower doses used in women to minimize androgenic side effects. Some practitioners start at 10–15 mg for women and 25–50 mg for men. Before initiating therapy, it is prudent to measure baseline DHEAS, total and free testosterone, SHBG, cortisol, and glucose/lipid panel. Common side effects include acne, oily skin, hair loss (in predisposed individuals), mood changes (irritability, anxiety), and hirsutism in women. Long-term safety beyond 2 years is not well established; high doses may raise estrogen levels in men, potentially increasing the risk of gynecomastia and, theoretically, prostate tumor growth, though causal evidence is limited.

Monitoring should include repeat hormone panels every 3–6 months, along with fasting glucose, HbA1c, and liver function tests. In men, prostate-specific antigen (PSA) should be checked at baseline and periodically. DHEA can interact with anticonvulsants (e.g., phenytoin, carbamazepine) by inducing cytochrome P450 enzymes, and with corticosteroids and insulin, requiring dose adjustments. Women who are pregnant or breastfeeding should avoid DHEA due to potential androgenic effects on the fetus or infant.

Testosterone Replacement Therapy: Who, When, and How

TRT is indicated only for men with symptomatic hypogonadism—defined as low morning total testosterone (<300 ng/dL) accompanied by symptoms such as decreased libido, erectile dysfunction, fatigue, depression, or loss of muscle mass. Available formulations include transdermal gels (e.g., AndroGel, Testim), intramuscular injections (testosterone cypionate or enanthate usually given every 1–2 weeks), subcutaneous pellets (Testopel) lasting 3–6 months, buccal tablets (Striant), and nasal gels. The goal is to restore testosterone to the mid-normal physiologic range (400–700 ng/dL). Benefits on glycemic control are modest but clinically meaningful, with HbA1c reductions of 0.4–1.0% in meta-analyses. Importantly, TRT should not be started in men with untreated severe obstructive sleep apnea, baseline hematocrit above 50%, or active prostate cancer (except low-risk, treated cases). In women, testosterone therapy is rarely used for diabetes and is reserved for hypoactive sexual desire disorder under specialist guidance; doses are one-tenth of male doses and monitored closely.

Contraindications and Precautions

Both DHEA and TRT require careful screening. Absolute contraindications for TRT include active prostate or breast cancer (in men), a palpable prostate nodule, and severe lower urinary tract symptoms (IPSS >19). For DHEA, absolute contraindications include hormone-sensitive cancers (prostate, breast, ovarian) and pregnancy/breastfeeding. Relative contraindications include a history of polycystic ovary syndrome (DHEA may increase androgens further), untreated hypothyroidism, and concurrent use of corticosteroids (potential for additive immunosuppression). Clinicians should also be aware that DHEA can lower HDL cholesterol in some individuals, though the clinical significance is uncertain.

Emerging Research and Future Directions

The field is rapidly evolving. Selective androgen receptor modulators (SARMs) are being developed to deliver anabolic effects on muscle and bone with reduced androgenic side effects on the prostate, skin, and hair. Early phase II trials in sarcopenia and cancer cachexia show improvements in lean mass and physical function, and some are being investigated for metabolic syndrome. However, none are yet approved for clinical use, and most are classified as investigational or misused as performance-enhancing drugs. DHEA analogs with enhanced anti-inflammatory properties are also in preclinical development, aiming to dissociate the anti-inflammatory effects from the hormonal activity.

Another promising avenue is personalized endocrine profiling. Advances in metabolomics, proteomics, and machine learning may soon allow clinicians to identify specific hormonal deficits—low DHEA with high cortisol, low free testosterone with normal SHBG, or impaired conversion to DHT—and tailor therapy accordingly. Large randomized controlled trials are still needed to establish definitive guidelines for hormonal optimization in diabetes, including appropriate endpoints such as cardiovascular events and long-term safety. The integration of continuous glucose monitoring (CGM) data with hormonal assessments could provide real-time insights into how daily fluctuations in steroids affect glycemic control.

Practical Recommendations for Patients and Practitioners

Key takeaway: Hormonal balance is an underappreciated yet modifiable factor in diabetes management. Assessment of DHEA and androgen status should be considered in patients with unexplained poor glycemic control, fatigue, loss of muscle mass, or mood disturbances.

  • For patients: Do not start DHEA without first discussing with your healthcare provider. Have baseline labs drawn, and avoid exceeding 50 mg/day unless under supervision. Report any side effects such as acne, mood changes, or irregular menstrual cycles promptly.
  • For clinicians: Incorporate morning total and free testosterone, DHEAS, SHBG, and cortisol (or a cortisol/DHEAS ratio) in the workup for hypogonadal symptoms or unexplained metabolic deterioration. Consider referral to an endocrinologist for complex cases involving PCOS, adrenal insufficiency, or multiple hormonal imbalances.
  • Lifestyle factors: Resistance training (at least 2–3 times per week), adequate sleep (7–9 hours), and stress reduction (mindfulness, yoga, or meditation) can naturally boost DHEA and androgen levels. Optimizing these should be the foundation of any hormonal intervention, as they improve overall metabolic health and may reduce the need for pharmaceutical supplementation.

Conclusion

DHEA and androgens are far more than reproductive hormones; they are integral to glucose homeostasis, inflammation control, and overall metabolic health. In type 2 diabetes, deficiencies in these steroids are common and may exacerbate disease progression. While supplementation offers promise, it is not a panacea and must be approached with caution, individualized dosing, and regular monitoring. Future research will refine patient selection and uncover new therapeutic targets, but for now, clinicians who integrate endocrine assessment into diabetes care can provide a more comprehensive and effective treatment strategy.

For further reading, consult the following authoritative resources: